- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00472199
Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)
A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period
The primary objective of the current study will be the evaluation of long-term efficacy of a 26-weeks treatment with pramipexole in patients with idiopathic moderate to severe Restless Legs Syndrome (RLS) in comparison to placebo.
The key secondary objectives are to assess the effects on clinical global impressions - global improvement (CGI-I) (based on CGI-I responder rate) and on RLS (based on IRLS responder rate) for 26 weeks under pramipexole in comparison to placebo. Further secondary objectives are to investigate the incidence and severity of augmentation and rebound and to assess the effects on patient global impression (PGI) (based on PGI responder rate), on RLS symptoms (based on the RLS-6 scales), on associated mood disturbance (based on item 10 of the IRLS), on pain in limbs (based on a visual analogue scale (VAS)), on quality of life in RLS (based on Johns Hopkins RLS-QoL), on general quality of life Short Form 36 (SF-36) and on safety (based on adverse events (AE) profile) of pramipexole in comparison to placebo.
연구 개요
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Bennebroek, 네덜란드
- 248.629.31001 Boehringer Ingelheim Investigational Site
-
Hoogwoud, 네덜란드
- 248.629.31005 Boehringer Ingelheim Investigational Site
-
Musselkanaal, 네덜란드
- 248.629.31006 Boehringer Ingelheim Investigational Site
-
Oude Pekela, 네덜란드
- 248.629.31002 Boehringer Ingelheim Investigational Site
-
Oude Pekela, 네덜란드
- 248.629.31003 Boehringer Ingelheim Investigational Site
-
Rijswijk, 네덜란드
- 248.629.31004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Berlin, 독일
- 248.629.4902 Boehringer Ingelheim Investigational Site
-
Berlin (Hellersdorf), 독일
- 248.629.4904 Boehringer Ingelheim Investigational Site
-
Berlin-Steglitz, 독일
- 248.629.4903 Boehringer Ingelheim Investigational Site
-
Bochum, 독일
- 248.629.4908 Boehringer Ingelheim Investigational Site
-
Ellwangen, 독일
- 248.629.4901 Boehringer Ingelheim Investigational Site
-
Herborn, 독일
- 248.629.4906 Boehringer Ingelheim Investigational Site
-
Leipzig, 독일
- 248.629.4905 Boehringer Ingelheim Investigational Site
-
Schwerin, 독일
- 248.629.4909 Boehringer Ingelheim Investigational Site
-
Würzburg, 독일
- 248.629.4907 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Edegem, 벨기에
- 248.629.3201 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, 스페인
- 248.629.3402 Boehringer Ingelheim Investigational Site
-
Granada, 스페인
- 248.629.3405 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 248.629.3401 Boehringer Ingelheim Investigational Site
-
San Sebastián, 스페인
- 248.629.3403 Boehringer Ingelheim Investigational Site
-
Valencia, 스페인
- 248.629.3406 Hospital Arnau de Vilanova
-
-
-
-
-
Bratislava, 슬로바키아
- 248.629.4204 Boehringer Ingelheim Investigational Site
-
Bratislava, 슬로바키아
- 248.629.4205 Boehringer Ingelheim Investigational Site
-
Brezno, 슬로바키아
- 248.629.4202 Boehringer Ingelheim Investigational Site
-
Kosice, 슬로바키아
- 248.629.4201 Boehringer Ingelheim Investigational Site
-
Martin, 슬로바키아
- 248.629.4203 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Carrigtwohill, 아일랜드
- 248.629.35301 Boehringer Ingelheim Investigational Site
-
Co. Kildare, 아일랜드
- 248.629.35302 Boehringer Ingelheim Investigational Site
-
Co. Tipperary, 아일랜드
- 248.629.35303 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Chorley, 영국
- 248.629.44003 Boehringer Ingelheim Investigational Site
-
Edgbaston, Birmingham, 영국
- 248.629.44006 Boehringer Ingelheim Investigational Site
-
Glasgow, 영국
- 248.629.44004 Boehringer Ingelheim Investigational Site
-
Manchester, 영국
- 248.629.44001 Boehringer Ingelheim Investigational Site
-
Reading, 영국
- 248.629.44002 Boehringer Ingelheim Investigational Site
-
Waterloo, Liverpool, 영국
- 248.629.44005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Innsbruck, 오스트리아
- 248.629.4302 Boehringer Ingelheim Investigational Site
-
Linz, 오스트리아
- 248.629.4304 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Espoo, 핀란드
- 248.629.35801 Boehringer Ingelheim Investigational Site
-
Helsinki, 핀란드
- 248.629.35805 Boehringer Ingelheim Investigational Site
-
Joensuu, 핀란드
- 248.629.35804 Boehringer Ingelheim Investigational Site
-
Oulu, 핀란드
- 248.629.35802 Boehringer Ingelheim Investigational Site
-
Tampere, 핀란드
- 248.629.35806 Boehringer Ingelheim Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Written informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local Institutional Review Board/Independent Ethics Committee (IRB/IEC) requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments
- Male or female out-patients aged 18-85 years
- Diagnosis of idiopathic RLS according to the clinical RLS criteria of the International Restless Legs Syndrome Study Group (IRLSSG) [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS.
- RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2)
- IRLS total score >15 at baseline (Visit 2)
Exclusion Criteria:
- Women of child-bearing potential (i.e. premenopausal women, or postmenopausal women less than 6 months after last menses) who do not use during the clinical trial an adequate method of contraception such as: double barrier protection (e.g. diaphragm or condom and spermicide), intrauterine device, hormonal therapy (oral, injectable, or subcutaneous), or partner's surgical sterilization
- Any woman of child-bearing potential not having a negative pregnancy test at screening
- Breastfeeding women
- Patients with known hypersensitivity to pramipexole or any other component of the investigational product or placebo tablets
- Diagnosis of augmentation under previous pharmacological RLS treatment
- Concomitant or previous pharmacologic therapy as follows: Any intake of dopamine agonists within 14 days prior to baseline (Visit 2); Any intake of levodopa within 14 days prior to baseline (Visit 2); Unsuccessful prior treatment with non-ergot dopamine agonists (e.g. pramipexole, ropinirole);
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Pramipexole
4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
|
|
위약 비교기: Placebo
4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks
기간: Baseline and 26 weeks
|
IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)
|
Baseline and 26 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Clinical Global Impression - Global Improvement (CGI-I) Responder Rate
기간: after 26 weeks of treatment
|
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)
|
after 26 weeks of treatment
|
International Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate
기간: after 26 weeks of treatment
|
IRLS response was defined as at least 50% reduction in IRLS total score from baseline.
IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)
|
after 26 weeks of treatment
|
Patient Global Impression (PGI) Responder Rate
기간: after 26 weeks of treatment
|
PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)
|
after 26 weeks of treatment
|
Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks
기간: baseline and 26 weeks of treatment
|
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
|
baseline and 26 weeks of treatment
|
Change From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
|
Baseline and 26 weeks of treatment
|
Change From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks
기간: baseline and 26 weeks of treatment
|
The question was rated on an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
|
baseline and 26 weeks of treatment
|
Change From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
|
Baseline and 26 weeks of treatment
|
Change From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
|
Baseline and 26 weeks of treatment
|
Change From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
|
Baseline and 26 weeks of treatment
|
Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)
|
Baseline and 26 weeks of treatment
|
Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)
|
Baseline and 26 weeks of treatment
|
Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks
기간: Baseline and 26 weeks of treatment
|
RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life
|
Baseline and 26 weeks of treatment
|
Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating less bodily pain
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension General Health After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better health status
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better mental health
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better physical functioning
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better social functioning
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Vitality After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better vitality
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better health
|
Baseline and 26 weeks
|
Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks
기간: Baseline and 26 weeks
|
Score ranging from 0 to 100 with higher scores indicating better health
|
Baseline and 26 weeks
|
Diagnosis of Classified Augmentation According to Independent Expert Panel
기간: after at least 4 weeks of treatment
|
Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.
|
after at least 4 weeks of treatment
|
Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation
기간: after at least 1 week of treatment discontinuation
|
Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation). Assessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline. |
after at least 1 week of treatment discontinuation
|
Baseline, Week 26 Mean Supine Systolic Blood Pressure
기간: Baseline, Week 26
|
Baseline, Week 26
|
|
Baseline, Week 26 Mean Standing Systolic Blood Pressure
기간: Baseline, Week 26
|
Baseline, Week 26
|
|
Baseline, Week 26 Mean Supine Diastolic Blood Pressure
기간: Baseline, Week 26
|
Baseline, Week 26
|
|
Baseline, Week 26 Mean Standing Diastolic Blood Pressure
기간: Baseline, Week 26
|
Baseline, Week 26
|
|
Baseline, Week 26 Mean Supine Pulse Rate
기간: Baseline, Week 26
|
Baseline, Week 26
|
|
Baseline, Week 26 Mean Standing Pulse Rate
기간: Baseline, Week 26
|
Baseline, Week 26
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
하지불안증후군에 대한 임상 시험
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)완전한
-
Basaksehir Cam & Sakura Şehir Hospital완전한
-
China Medical University Hospital알려지지 않은
-
Wolfson Medical Center빼는Ovarian Hyperstimulation Syndrome(OHSS)의 위험 감소를 위한 Coasting에 대한 GnRH 길항제의 증량 투여
-
Jazz Pharmaceuticals모병결절성 경화증 복합 환자의 발작 | Dravet Syndrome 참가자의 발작 | 레녹스-가스토 증후군 참가자의 발작미국
-
Cure CMD모병Emery-Dreifuss 근이영양증 | 선천성 근무력증 증후군 | 림거들 근이영양증 | ITGA7(인테그린 알파-7) 결핍을 동반한 선천성 근이영양증 | 알파-디스트로글리칸병증(심각한 간질을 동반한 디스트로글리칸의 선천성 근이영양증 및 비정상적인 글리코실화) | 알파-디스트로글리칸병증(TRAPPC11 돌연변이로 인한 지방간 및 영아 발병 백내장을 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸 및 간질의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸병증... 그리고 다른 조건미국
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research Foundation 그리고 다른 협력자들모병미토콘드리아 질병 | 색소 성 망막염 | 중증 근무력증 | 호산구성 위장염 | 다계통 위축 | 평활근육종 | 백질이영양증 | 항문 누공 | 척수소뇌성 운동실조증 3형 | 프리드라이히 실조증 | 케네디병 | 라임 병 | 혈구탐식림프조직구증 | 척수소뇌성 운동실조증 1형 | 척수소뇌성 운동실조증 2형 | 척수소뇌성 실조증 6형 | 윌리엄스 증후군 | 히르슈스프룽병 | 글리코겐 축적병 | 가와사키병 | 짧은 창자 증후군 | 저인산증 | 레버 선천성 흑암시 | 입내 | 심장이완불능증 | 다발성 내분비선 종양 | 레이 증후군 | 애디슨병 | 제2형 다발성내분비선종양 | 경피증 | 제1형 다발성내분비선종양 | 다발성 내분비선 종양 유형 2A | 다발성 내분비선 종양 유형 2B | 비정형 용혈성... 그리고 다른 조건미국, 호주
위약에 대한 임상 시험
-
AJU Pharm Co., Ltd.OM Pharma SA모병
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로